<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "http://jats.nlm.nih.gov/publishing/1.0/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="article-commentary" dtd-version="1.0" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="issn">1043-3155</journal-id>
<journal-id journal-id-type="nlm-ta">Pediatr Neurol Briefs</journal-id>
<journal-id journal-id-type="pmc">pedneurbriefs</journal-id>
<journal-id journal-id-type="iso-abbrev">Pediatr Neurol Briefs</journal-id>
<journal-title-group>
<journal-title>Pediatric Neurology Briefs</journal-title>
<abbrev-journal-title>Pediatr Neurol Briefs</abbrev-journal-title>
</journal-title-group>
<issn pub-type="epub">2166-6482</issn>
<issn pub-type="ppub">1043-3155</issn>
<issn-l>2166-3155</issn-l>
<publisher>
<publisher-name>Pediatric Neurology Briefs Publishers</publisher-name>
<publisher-loc>Chicago, IL, USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">PNB-2012-26-10-6</article-id>
<article-id pub-id-type="doi">10.15844/pedneurbriefs-26-10-6</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Seizure Disorders</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v2">
<subject>Neurology</subject>
<subject>Pediatrics</subject>
<subject>Nervous System Diseases</subject>
<subject>Child Development</subject>
<subject>Brain Diseases</subject>
<subject>Neurosurgery</subject>
<subject>Child</subject>
<subject>Infant</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Outcome of Therapies in Refractory Convulsive Status Epilepticus</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0173-7931</contrib-id>
<name>
<surname>Millichap</surname>
<given-names>J. Gordon</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="AF0001">1</xref>
<xref ref-type="aff" rid="AF0002">2</xref>
<xref ref-type="corresp" rid="cor1">&#x002A;</xref>
</contrib>
</contrib-group>
<aff id="AF0001">
<label>1</label>Division of Neurology, Ann &#x0026; Robert H. Lurie Children&#x0027;s Hospital of Chicago, Chicago, IL</aff>
<aff id="AF0002">
<label>2</label>Departments of Pediatrics and Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL</aff>
<author-notes>
<corresp id="cor1">
<label>&#x002A;</label>Correspondence: Dr. J. Gordon Millichap, E-mail: <email xlink:href="jgmillichap@northwestern.edu">jgmillichap@northwestern.edu</email>
</corresp>
</author-notes>
<pub-date date-type="pub" publication-format="print">
<month>10</month>
<year>2012</year>
</pub-date>
<pub-date date-type="pub" publication-format="electronic">
<day>01</day>
<month>11</month>
<year>2015</year>
</pub-date>
<volume>26</volume>
<issue>10</issue>
<fpage>77</fpage>
<lpage>78</lpage>
<permissions>
<copyright-statement>Copyright: &#x00A9; 2012 The Author(s)</copyright-statement>
<copyright-year>2012</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This work is licensed under the <uri xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International License</uri>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
</license>
</permissions>
<related-article id="R1" related-article-type="commentary-article" ext-link-type="doi" xlink:href="10.1093/brain/aws091" vol="135" page="2314">
<article-title>The outcome of therapies in refractory and super-refractory convulsive status epilepticus and recommendations for therapy</article-title>
</related-article>
<abstract abstract-type="web-summary" specific-use="electronic-only">
<p>Researchers at Queen Square, London, review the long-term outcome of therapies in refractory convulsive status epilepticus.</p>
</abstract>
<kwd-group>
<kwd>Pyridoxine Infusions</kwd>
<kwd>Immunological Therapy</kwd>
<kwd>Ketogenic Diet</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Researchers at Queen Square, London, review the long-term outcome of therapies in refractory convulsive status epilepticus. Of 596 patients reported (51% of the total of 1168). 201 (35%) died, 79 (13%) had severe neurological deficit, 80 (13%) mild neurological deficit, 22 (4%) with undefined deficit, and 208 (35%) recovered to baseline. The quality of reported outcome data is generally poor, and only broad recommendations for optimal therapy are possible. General anesthesia remains the backbone of therapy, and immediate control is achieved in two-thirds of cases. Agents analyzed include thiopental/pentobarbital, midazolam, propofol, and ketamine, each having advantages and disadvantages. Children are least likely to be treated with propofol because of risk of propofol infusion syndrome, with myocardial failure and high mortality on prolonged infusion. Ketamine is a second-line drug with potential neurotoxic effects. First-line anesthesia therapy should be used with intensive care support and treatment of the underlying cause. Second-line therapies include hypothermia, magnesium and pyridoxine infusions, immunological therapy, ketogenic diet, and neurosurgery. Antiepileptic drug therapy should be used concurrently with anesthesia but outcome data are sparse. Choice of drug regimens include polytherapy with 2 antiepileptic drugs, high-dose, avoid frequent switching, drugs with low interaction potential, predictable kinetics, drugs without renal or hepatic toxicity, and avoidance of GABAergic AEDs. [<xref ref-type="bibr" rid="CIT0001">1</xref>]</p>
<p>COMMENT. The authors comment that the most striking conclusion of their review of literature was the poor quality of outcome data. Only broad recommendations were possible from the analysis of reports. Refractory status epilepticus is heterogeneous and prognosis depends on factors other than treatment, such as age and etiology. General anesthesia is generally effective, and the rate of withdrawal seizures is lower than often quoted. Propofol infusion syndrome is a rare but frequently fatal complication caused by impaired fatty acid oxidation. The hallmarks are metabolic acidosis, lipemia, rhabdomyolysis and myocardial failure. A 10-year-old boy with status epilepticus treated with propofol developed fatal propofol infusion syndrome when a ketogenic diet was initiated. [<xref ref-type="bibr" rid="CIT0002">2</xref>]</p>
</body>
<back>
<ref-list>
<ref id="CIT0001">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferlisi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Shorvon</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>The outcome of therapies in refractory and super-refractory convulsive status epilepticus and recommendations for therapy</article-title>
<source>Brain</source>
<year>2012</year>
<month>Aug</month>
<volume>135</volume>
<issue>Pt 8</issue>
<fpage>2314</fpage>
<lpage>28</lpage>
<pub-id pub-id-type="doi">10.1093/brain/aws091</pub-id>
<pub-id pub-id-type="pmid">22577217</pub-id>
</element-citation>
</ref>
<ref id="CIT0002">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baumeister</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Oberhoffer</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Liebhaber</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Kunkel</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Eberhardt</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Holthausen</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group>
<article-title>Fatal propofol infusion syndrome in association with ketogenic diet</article-title>
<source>Neuropediatrics</source>
<year>2004</year>
<month>Aug</month>
<volume>35</volume>
<issue>4</issue>
<fpage>250</fpage>
<lpage>2</lpage>
<pub-id pub-id-type="doi">10.1055/s-2004-820992</pub-id>
<pub-id pub-id-type="pmid">15328567</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
